NHS-BiB
|
- $262 - $1100
- Product name: NHS-BiB
- CAS: 728034-24-0
- MF: C8H10BrNO4
- MW: 264.07
- EINECS:
- MDL Number:MFCD28053557
- Synonyms:NHS ATRP initiator;NHS protected Bromoisobutyrate;NHS-BiB;N-Hydroxysuccinimidyl 2-bromo-2-methylpropionate;2-Bromoisobutanoic acid N-hydroxysuccinimide ester 98% (GC);1-(2-Bromo-2-methyl-1-oxopropoxy)-2,5-pyrrolidinedione;2,5-Dioxopyrrolidin-1-yl 2-bromo-2-methylpropanoate;2-Bromo-2-methyl-propanoic acid 2,5-dioxo-1-pyrrolidinyl ester
3 prices
Selected condition：
Brand
- A1 Biochem Labs
- Sigma-Aldrich
Package
- 1g
- 5G
- 10g
- ManufacturerA1 Biochem Labs
- Product number6568040
- Product descriptionPropanoicacid,2-bromo-2-methyl-,2,5-dioxo-1-pyrrolidinylester 95%
- Packaging5G
- Price$750
- Updated2021-12-16
- Buy
- ManufacturerA1 Biochem Labs
- Product number6568040
- Product descriptionPropanoicacid,2-bromo-2-methyl-,2,5-dioxo-1-pyrrolidinylester 95%
- Packaging10g
- Price$1100
- Updated2021-12-16
- Buy
- ManufacturerSigma-Aldrich
- Product number792047
- Product description2-Bromoisobutanoic acid N-hydroxysuccinimide ester 98% (GC)
- Packaging1g
- Price$262
- Updated2024-03-01
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| A1 Biochem Labs | 6568040 | Propanoicacid,2-bromo-2-methyl-,2,5-dioxo-1-pyrrolidinylester 95% | 5G | $750 | 2021-12-16 | Buy |
| A1 Biochem Labs | 6568040 | Propanoicacid,2-bromo-2-methyl-,2,5-dioxo-1-pyrrolidinylester 95% | 10g | $1100 | 2021-12-16 | Buy |
| Sigma-Aldrich | 792047 | 2-Bromoisobutanoic acid N-hydroxysuccinimide ester 98% (GC) | 1g | $262 | 2024-03-01 | Buy |
Properties
Melting point :135-140°C
storage temp. :2-8°C
form :liquid
storage temp. :2-8°C
form :liquid
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|